Novel antibody–drug conjugates for triple negative breast cancer

Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagayama, Aiko, Vidula, Neelima, Ellisen, Leif, Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
TNBC in 2019: Promising Signals for the Special Collection Treatment of a Formidable Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222243/
https://www.ncbi.nlm.nih.gov/pubmed/32426047
http://dx.doi.org/10.1177/1758835920915980
_version_ 1783533530195689472
author Nagayama, Aiko
Vidula, Neelima
Ellisen, Leif
Bardia, Aditya
author_facet Nagayama, Aiko
Vidula, Neelima
Ellisen, Leif
Bardia, Aditya
author_sort Nagayama, Aiko
collection PubMed
description Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.
format Online
Article
Text
id pubmed-7222243
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72222432020-05-18 Novel antibody–drug conjugates for triple negative breast cancer Nagayama, Aiko Vidula, Neelima Ellisen, Leif Bardia, Aditya Ther Adv Med Oncol TNBC in 2019: Promising Signals for the Special Collection Treatment of a Formidable Disease Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC. SAGE Publications 2020-05-11 /pmc/articles/PMC7222243/ /pubmed/32426047 http://dx.doi.org/10.1177/1758835920915980 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage)
spellingShingle TNBC in 2019: Promising Signals for the Special Collection Treatment of a Formidable Disease
Nagayama, Aiko
Vidula, Neelima
Ellisen, Leif
Bardia, Aditya
Novel antibody–drug conjugates for triple negative breast cancer
title Novel antibody–drug conjugates for triple negative breast cancer
title_full Novel antibody–drug conjugates for triple negative breast cancer
title_fullStr Novel antibody–drug conjugates for triple negative breast cancer
title_full_unstemmed Novel antibody–drug conjugates for triple negative breast cancer
title_short Novel antibody–drug conjugates for triple negative breast cancer
title_sort novel antibody–drug conjugates for triple negative breast cancer
topic TNBC in 2019: Promising Signals for the Special Collection Treatment of a Formidable Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222243/
https://www.ncbi.nlm.nih.gov/pubmed/32426047
http://dx.doi.org/10.1177/1758835920915980
work_keys_str_mv AT nagayamaaiko novelantibodydrugconjugatesfortriplenegativebreastcancer
AT vidulaneelima novelantibodydrugconjugatesfortriplenegativebreastcancer
AT ellisenleif novelantibodydrugconjugatesfortriplenegativebreastcancer
AT bardiaaditya novelantibodydrugconjugatesfortriplenegativebreastcancer

Ejemplares similares